Literature DB >> 19808231

Key comorbid conditions that are predictive of survival among hemodialysis patients.

Dana Miskulin1, Jennifer Bragg-Gresham, Brenda W Gillespie, Francesca Tentori, Ronald L Pisoni, Hocine Tighiouart, Andrew S Levey, Friedrich K Port.   

Abstract

BACKGROUND AND OBJECTIVES: Abstracting information about comorbid illnesses from the medical record can be time-consuming, particularly when a large number of conditions are under consideration. We sought to determine which conditions are most prognostic and whether comorbidity continues to contribute to a survival model once laboratory and clinical parameters have been accounted for. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Comorbidity data were abstracted from the medical records of Dialysis Outcomes and Practice Pattern Study (DOPPS) I, II, and III participants using a standardized questionnaire. Models that were composed of different combinations of comorbid conditions and case-mix factors were compared for explained variance (R(2)) and discrimination (c statistic).
RESULTS: Seventeen comorbid conditions account for 96% of the total explained variance that would result if 45 comorbidities that were expected to be predictive of survival were added to a demographics-adjusted survival model. These conditions together had more discriminatory power (c statistic 0.67) than age alone (0.63) or serum albumin (0.60) and were equivalent to a combination of routine laboratory and clinical parameters (0.67). The strength of association of the individual comorbidities lessened when laboratory/clinical parameters were added, but all remained significant. The total R(2) of a model adjusted for demographics and laboratory/clinical parameters increased from 0.13 to 0.17 upon addition of comorbidity.
CONCLUSIONS: A relatively small list of comorbid conditions provides equivalent discrimination and explained variance for survival as a more extensive characterization of comorbidity. Comorbidity adds to the survival model a modest amount of independent prognostic information that cannot be substituted by clinical/laboratory parameters.

Entities:  

Mesh:

Year:  2009        PMID: 19808231      PMCID: PMC2774950          DOI: 10.2215/CJN.00640109

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  17 in total

1.  Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial.

Authors:  D C Miskulin; N V Athienites; G Yan; A A Martin; D B Ornt; J W Kusek; K B Meyer; A S Levey
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

Review 2.  Obesity and survival on dialysis.

Authors:  Abdulla K Salahudeen
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

3.  Comorbidity and its change predict survival in incident dialysis patients.

Authors:  Dana C Miskulin; Klemens B Meyer; Alice A Martin; Nancy E Fink; Josef Coresh; Neil R Powe; Michael J Klag; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2003-01       Impact factor: 8.860

4.  Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease.

Authors:  Dana C Miskulin; Klemens B Meyer; Nicolaos V Athienites; Alice A Martin; Norma Terrin; Jane V Marsh; Nancy E Fink; Josef Coresh; Neil R Powe; Mike J Klag; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

5.  A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients.

Authors:  S Beddhu; F J Bruns; M Saul; P Seddon; M L Zeidel
Journal:  Am J Med       Date:  2000-06-01       Impact factor: 4.965

6.  A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients.

Authors:  K Kalantar-Zadeh; J D Kopple; G Block; M H Humphreys
Journal:  Am J Kidney Dis       Date:  2001-12       Impact factor: 8.860

7.  Adjustment for comorbidity in studies on health status in ESRD patients: which comorbidity index to use?

Authors:  Jeannette G Van Manen; Johanna C Korevaar; Friedo W Dekker; Elisabeth W Boeschoten; Patrick M M Bossuyt; Raymond T Krediet
Journal:  J Am Soc Nephrol       Date:  2003-02       Impact factor: 10.121

8.  Effect of dialysis dose and membrane flux in maintenance hemodialysis.

Authors:  Garabed Eknoyan; Gerald J Beck; Alfred K Cheung; John T Daugirdas; Tom Greene; John W Kusek; Michael Allon; James Bailey; James A Delmez; Thomas A Depner; Johanna T Dwyer; Andrew S Levey; Nathan W Levin; Edgar Milford; Daniel B Ornt; Michael V Rocco; Gerald Schulman; Steve J Schwab; Brendan P Teehan; Robert Toto
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

9.  Medicare and Medicaid programs; conditions for coverage for end-stage renal disease facilities. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2008-04-15

10.  How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices.

Authors:  Jeannette G van Manen; Johanna C Korevaar; Friedo W Dekker; Elisabeth W Boeschoten; Patrick M M Bossuyt; Raymond T Krediet
Journal:  Am J Kidney Dis       Date:  2002-07       Impact factor: 8.860

View more
  34 in total

1.  Chronic kidney disease: Levels of phosphorus and patient outcomes.

Authors:  Robert N Foley
Journal:  Nat Rev Nephrol       Date:  2011-06-28       Impact factor: 28.314

2.  Predicting potential survival benefit of renal transplantation in patients with chronic kidney disease.

Authors:  Carl van Walraven; Peter C Austin; Greg Knoll
Journal:  CMAJ       Date:  2010-03-29       Impact factor: 8.262

3.  Disparities in symptom burden and renal transplant eligibility: a pilot study.

Authors:  Nathaniel Berman; Kaylan Christianer; Jordan Roberts; Rachel Feldman; M Cary Reid; Rouzi Shengelia; Jeanne Teresi; Joseph Eimicke; Brian Eiss; Ronald Adelman
Journal:  J Palliat Med       Date:  2013-10-10       Impact factor: 2.947

4.  Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.

Authors:  Martin Wagner; David Ansell; David M Kent; John L Griffith; David Naimark; Christoph Wanner; Navdeep Tangri
Journal:  Am J Kidney Dis       Date:  2011-04-12       Impact factor: 8.860

5.  Activity of daily living disability and dialysis mortality: better prediction using metrics of aging.

Authors:  Mara A McAdams-Demarco; Andrew Law; Jacqueline M Garonzik-Wang; Luis Gimenez; Bernard G Jaar; Jeremy D Walston; Dorry L Segev
Journal:  J Am Geriatr Soc       Date:  2012-10       Impact factor: 5.562

Review 6.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

7.  Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism.

Authors:  Diana Moldovan; Simona Racasan; Ina Maria Kacso; Crina Rusu; Alina Potra; Cosmina Bondor; Ioan Mihai Patiu; Mirela Gherman-Căprioară
Journal:  Int Urol Nephrol       Date:  2015-09-16       Impact factor: 2.370

8.  End-stage renal disease: a new comorbidity index for estimating mortality risk in ESRD.

Authors:  Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2010-07       Impact factor: 28.314

9.  A validation study of the Canadian Organ Replacement Register.

Authors:  Louise M Moist; Heather A Richards; Dana Miskulin; Charmaine E Lok; Karen Yeates; Amit X Garg; Lilyanna Trpeski; Ann Chapman; Joseph Amuah; Brenda R Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2011-01-21       Impact factor: 8.237

10.  Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS.

Authors:  Manish M Sood; Maria Larkina; Jyothi R Thumma; Francesca Tentori; Brenda W Gillespie; Shunichi Fukuhara; David C Mendelssohn; Kevin Chan; Patricia de Sequera; Paul Komenda; Claudio Rigatto; Bruce M Robinson
Journal:  Kidney Int       Date:  2013-05-15       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.